Mobocertinib (TAK-788) has received FDA Priority Review for the treatment of adult patients with epidermal growth factor receptor Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer, as detected by an FDA-approved test, who have received prior platinum-based chemotherapy.
The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.
